Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

x ray of sinusitis and nasal polyps Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter ...

Nasal polyps are painless, teardrop-shaped growths that form in your nose or sinuses. They’re most common where the sinuses near your eyes and cheekbones drain into your nose. Nasal polyps are not ...

Nasal polyps are small growths that develop from the nasal tissue that blocks sinus cavities, preventing the mucus from draining properly and leading to sinus infections. The restriction of air ...

Not only adults, nasal polyps can also occur in children. Polyps are an inflammation of the nasal membranes and sinuses that lasts more than 12 weeks. This condition is actually a soft, painless, ...

Please provide your email address to receive an email when new articles are posted on . Patients with nasal polyposis often experience chronic rhinosinusitis, a high symptom burden and poor quality of ...

Getting a cold once or twice a few months is normal, but what about a persistently blocked nose that lingers for weeks and causes ongoing discomfort? It may be tempting to ignore, but persistent nasal ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Symptoms often include facial pressure, congestion and fatigue — It affects about 37 million Americans each year — Infections ...

The approval was based on data from the phase 3 SYNAPSE study that evaluated mepolizumab as an add-on maintenance treatment in over 400 adults with CRSwNP. The Food and Drug Administration (FDA) has ...

A new add-on therapy administered every six months targets key inflammatory pathways in asthma and chronic rhinosinusitis ...